Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continuing their series celebrating ‘amazing people at Oxford who you should know about’, The Oxford ScienceBlog talks to Dayne Beccano-Kelly, an electrophysiologist and a Career Development Fellow in Oxford Parkinson’s Disease Centre, in the Department of Physiology, Anatomy and Genetics.

Image of Dayne Beccano-Kelly

With more than ten years’ experience in the field, Dayne discusses his research using human neurones to improve treatments and the quality of life for people with neurodegenerative conditions such as Parkinson’s disease. He also shares how he is aiming to tackle the lack of BAME leadership opportunities in STEM, by mentoring and inspiring black and minority ethnic scientists of tomorrow.

How would you describe your journey to Oxford?

I am from Cardiff originally, and took my undergraduate degree at Leeds University in bio-chemistry, as a route into medicine. But, after my first year, I changed my mind with a stint in research, as part of my year in industry.

Time and experience showed me that what I really wanted to do was science research, helping people, but being the one to garner the knowledge that would help. It is fun to be continually asking the questions, and driving the conversation on known scientific knowledge.

Was Oxford what you expected it to be?

Oxford is a melting pot of scientific ideas that are often brewing a stone’s throw away, which makes it easier to interact with other scientists and develop collaborations.

I have been here four years now and don’t feel marginalised at Oxford. I expected there to be a low number of BAME academics at Oxford, because there have been at every other institution.

Having lived in Vancouver directly before this, which I loved in a different way, I can feel the contrast. It’s great to be surrounded by so much history. Vancouver is younger than Arsenal FC, my football team.

Read the full interview (Oxford Science Blog)

Similar stories

Major grant to strengthen research and benefit patients

Oxford University Hospitals (OUH) has made a grant of £11.5 million to the University of Oxford, which the University will match with other funding, to allow the development of major clinical research facilities which have the potential to support the introduction of innovative and ground-breaking treatments for patients.

Dr Lennard Lee awarded ACP McElwain Prize for contributions to medical oncology

Dr Lee (Department of Oncology) received the award to acknowledge his contributions during the COVID-19 pandemic, through the establishment of the UK Coronavirus Cancer Monitoring Project.

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Ivermectin to be investigated as a possible treatment for COVID-19 in the PRINCIPLE trial

From today, ivermectin is being investigated in the UK as part of the Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.